Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma
Saved in:
| Published in: | Liver Cancer International |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1868552915817332736 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Liver Cancer International |
| description | |
| discipline_display | Internal Medicine |
| discipline_facet | Internal Medicine |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:67938 |
| institution | FRELIP |
| journal_source_facet | Liver Cancer International |
| last_indexed | 2026-06-20T21:28:40.759Z |
| publishDate | 2026 |
| publishDateSort | 2026 |
| record_format | rss_article |
| spellingShingle | Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma Internal Medicine General Internal Medicine |
| sub_discipline_display | General |
| sub_discipline_facet | General |
| subject_display | Internal Medicine General Internal Medicine |
| subject_facet | Internal Medicine General Internal Medicine |
| title | Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma |
| title_alt | Impacto de los eventos adversos inmunomediados frecuentes en la continuidad del tratamiento y los resultados durante la terapia con durvalumab más tremelimumab para el carcinoma hepatocelular irresecable Impact des événements indésirables immuno-médiés fréquents sur la continuité du traitement et les résultats lors du traitement par Durvalumab plus Trémélimumab pour le carcinome hépatocellulaire non résécable Impacto de Eventos Adversos Imunomediados Frequentes na Continuidade do Tratamento e Desfechos Durante Terapia com Durvalumabe mais Tremelimumabe para Carcinoma Hepatocelular Irressecável |
| title_auth | Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma |
| title_es_txt | Impacto de los eventos adversos inmunomediados frecuentes en la continuidad del tratamiento y los resultados durante la terapia con durvalumab más tremelimumab para el carcinoma hepatocelular irresecable |
| title_fr_txt | Impact des événements indésirables immuno-médiés fréquents sur la continuité du traitement et les résultats lors du traitement par Durvalumab plus Trémélimumab pour le carcinome hépatocellulaire non résécable |
| title_full | Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma |
| title_fullStr | Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma |
| title_full_unstemmed | Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma |
| title_pt_txt | Impacto de Eventos Adversos Imunomediados Frequentes na Continuidade do Tratamento e Desfechos Durante Terapia com Durvalumabe mais Tremelimumabe para Carcinoma Hepatocelular Irressecável |
| title_short | Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma |
| title_sort | impact of frequent immune‐mediated adverse events on treatment continuity and outcomes during durvalumab plus tremelimumab therapy for unresectable hepatocellular carcinoma |
| topic | Internal Medicine General Internal Medicine |
| url | https://onlinelibrary.wiley.com/doi/10.1002/lci2.70042?af=R |